ANAB PE Ratio & Valuation,Is ANAB Overvalued

ANAB Relative Valuation

ANAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ANAB is overvalued; if below, it's undervalued.

Historical Valuation

AnaptysBio Inc (ANAB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.54 is considered Undervalued compared with the five-year average of -3.88. The fair price of AnaptysBio Inc (ANAB) is between 481.30 to 689.67 according to relative valuation methord. Compared to the current price of 44.58 USD , AnaptysBio Inc is Undervalued By 90.74%.

Relative Value

Fair Zone

481.30-689.67

Current Price：44.58

90.74%

Undervalued

-21.50

16.79

EV/EBITDA

AnaptysBio Inc. (ANAB) has a current EV/EBITDA of 16.79. The 5-year average EV/EBITDA is -1.87. The thresholds are as follows: Strongly Undervalued below -12.51, Undervalued between -12.51 and -7.19, Fairly Valued between 3.45 and -7.19, Overvalued between 3.45 and 8.77, and Strongly Overvalued above 8.77. The current Forward EV/EBITDA of 16.79 falls within the Strongly Overvalued range.

-28.30

EV/EBIT

AnaptysBio Inc. (ANAB) has a current EV/EBIT of -28.30. The 5-year average EV/EBIT is 0.30. The thresholds are as follows: Strongly Undervalued below -40.02, Undervalued between -40.02 and -19.86, Fairly Valued between 20.45 and -19.86, Overvalued between 20.45 and 40.61, and Strongly Overvalued above 40.61. The current Forward EV/EBIT of -28.30 falls within the Undervalued range.

8.54

AnaptysBio Inc. (ANAB) has a current PS of 8.54. The 5-year average PS is 29.32. The thresholds are as follows: Strongly Undervalued below -20.56, Undervalued between -20.56 and 4.38, Fairly Valued between 54.25 and 4.38, Overvalued between 54.25 and 79.19, and Strongly Overvalued above 79.19. The current Forward PS of 8.54 falls within the Historic Trend Line -Fairly Valued range.

-23.39

P/OCF

AnaptysBio Inc. (ANAB) has a current P/OCF of -23.39. The 5-year average P/OCF is 18.42. The thresholds are as follows: Strongly Undervalued below -136.34, Undervalued between -136.34 and -58.96, Fairly Valued between 95.79 and -58.96, Overvalued between 95.79 and 173.17, and Strongly Overvalued above 173.17. The current Forward P/OCF of -23.39 falls within the Historic Trend Line -Fairly Valued range.

-19.22

P/FCF

AnaptysBio Inc. (ANAB) has a current P/FCF of -19.22. The 5-year average P/FCF is -6.34. The thresholds are as follows: Strongly Undervalued below -36.39, Undervalued between -36.39 and -21.36, Fairly Valued between 8.69 and -21.36, Overvalued between 8.69 and 23.72, and Strongly Overvalued above 23.72. The current Forward P/FCF of -19.22 falls within the Historic Trend Line -Fairly Valued range.

AnaptysBio Inc (ANAB) has a current Price-to-Book (P/B) ratio of -42.07. Compared to its 3-year average P/B ratio of 12.13 , the current P/B ratio is approximately -446.70% higher. Relative to its 5-year average P/B ratio of 8.07, the current P/B ratio is about -621.59% higher. AnaptysBio Inc (ANAB) has a Forward Free Cash Flow (FCF) yield of approximately -11.68%. Compared to its 3-year average FCF yield of -17.40%, the current FCF yield is approximately -32.90% lower. Relative to its 5-year average FCF yield of -12.34% , the current FCF yield is about -5.39% lower.

-42.65

P/B

Median3y

12.13

Median5y

8.07

-11.68

FCF Yield

Median3y

-17.40

Median5y

-12.34

Competitors Valuation Multiple

The average P/S ratio for ANAB's competitors is 0.00, providing a benchmark for relative valuation. AnaptysBio Inc Corp (ANAB) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 154.26%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ANAB increased by 244.11% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.14 to -15.82.

The secondary factor is the Revenue Growth, contributed 154.26%to the performance.

Overall, the performance of ANAB in the past 1 year is driven by P/E Change. Which is more unsustainable.

154.26%

30.02M → 76.32M

Revenue Growth

-118.09%

-109.44 → 19.80

Margin Expansion

207.94%

-5.14 → -15.82

P/E Change

244.11%

13.24 → 45.56

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is AnaptysBio Inc (ANAB) currently overvalued or undervalued?

What is AnaptysBio Inc (ANAB) fair value?

ANAB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of AnaptysBio Inc (ANAB) is between 481.30 to 689.67 according to relative valuation methord.

How does ANAB's valuation metrics compare to the industry average?

What is the current P/B ratio for AnaptysBio Inc (ANAB) as of Dec 16 2025?

As of Dec 16 2025, AnaptysBio Inc (ANAB) has a P/B ratio of -42.07. This indicates that the market values ANAB at -42.07 times its book value.

What is the current FCF Yield for AnaptysBio Inc (ANAB) as of Dec 16 2025?

As of Dec 16 2025, AnaptysBio Inc (ANAB) has a FCF Yield of -11.68%. This means that for every dollar of AnaptysBio Inc’s market capitalization, the company generates -11.68 cents in free cash flow.

What is the current Forward P/E ratio for AnaptysBio Inc (ANAB) as of Dec 16 2025?

As of Dec 16 2025, AnaptysBio Inc (ANAB) has a Forward P/E ratio of -21.21. This means the market is willing to pay $-21.21 for every dollar of AnaptysBio Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for AnaptysBio Inc (ANAB) as of Dec 16 2025?

As of Dec 16 2025, AnaptysBio Inc (ANAB) has a Forward P/S ratio of 8.54. This means the market is valuing ANAB at $8.54 for every dollar of expected revenue over the next 12 months.

ANAB Valuation